|
AFAP1-AS1
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Our findings will help to better understand the underlying mechanism of high AFAP1-AS1 expression in tumorigenesis and to develop new strategies for therapeutic high expression of AFAP1-AS1 in NPC.
|
30854123 |
2019 |
|
AFAP1-AS1
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Long non-coding RNA AFAP1-AS1 is an important tumor-associated lncRNA and its aberrant expression has been found in many malignancies so far, including pancreatic ductal adenocarcinoma, cholangiocarcinoma, gallbladder cancer, hepatocellular carcinoma, gastric cancer, colorectal cancer, esophageal cancer, nasopharyngeal carcinoma, lung cancer, ovarian cancer, breast cancer, retinoblastoma, laryngeal cancer, tongue squamous cell carcinoma and thyroid cancer.
|
30173945 |
2018 |
|
AFAP1-AS1
|
0.090 |
Biomarker
|
disease |
BEFREE |
In this study, we determined that AFAP1-AS1 functions as a competing endogenous RNA in NPC to regulate the Rho/Rac pathway through miR-423-5p.
|
30326930 |
2018 |
|
AFAP1-AS1
|
0.090 |
Biomarker
|
disease |
BEFREE |
In previous investigations, lncRNA, AFAP1-AS1 has been found to be associated with several cancers, including nasopharyngeal carcinoma, lung cancer and esophageal adenocarcinoma.
|
28670387 |
2017 |
|
AFAP1-AS1
|
0.090 |
Biomarker
|
disease |
BEFREE |
Our present study indicates that circulating MALAT1, AFAP1-AS1 and AL359062 may represent novel serum biomarkers for NPC diagnosis and prognostic prediction after treatment.
|
28467811 |
2017 |
|
AFAP1-AS1
|
0.090 |
Biomarker
|
disease |
BEFREE |
We found that AFAP1-AS1 was a risk factor in the prognoses of lung cancer (pooled HR: 1.54; 95% CI: 1.01-2.34), digestive system cancer (pooled HR: 1.87; 95% CI: 1.45-2.41) and nasopharyngeal carcinoma (HR: 11.82; 95% CI: 5.09-27.46).
|
29254250 |
2017 |
|
AFAP1-AS1
|
0.090 |
Biomarker
|
disease |
BEFREE |
This study suggests that AFAP1-AS1 and PD-1 may be potential therapeutic targets in NPC and that patients with co-expression of AFAP1-AS1 and PD-1 may be ideal candidates for future clinical trials of anti-PD-1 immune therapy.
|
28380458 |
2017 |
|
AFAP1-AS1
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
LncRNA AFAP1-AS1 was found to be upregulated in hepatocellular carcinoma (HCC), lung cancer, colorectal cancer, esophageal adenocarcinoma (EAC), pancreatic ductal adenocarcinoma, and nasopharyngeal carcinoma, while its clinical value and potential function in ESCC are still unknown.
|
27577754 |
2016 |
|
AFAP1-AS1
|
0.090 |
Biomarker
|
disease |
BEFREE |
AFAP1-AS1 might be a potential novel marker that can predict cancer patient prognosis and as a potential therapeutic target for NPC.
|
26246469 |
2015 |